Scarica l'app Stockscreener
23.07
0.56%
-0.13
Dopo l'orario di chiusura:
23.00
-0.07
-0.30%
Precedente Chiudi:
$23.20
Aprire:
$23.04
Volume 24 ore:
44,922
Relative Volume:
0.43
Capitalizzazione di mercato:
$333.96M
Reddito:
$1.80M
Utile/perdita netta:
$1.76B
Rapporto P/E:
0.1944
EPS:
118.674
Flusso di cassa netto:
$-149.23M
1 W Prestazione:
-2.33%
1M Prestazione:
+56.30%
6M Prestazione:
+75.44%
1 anno Prestazione:
+71.52%
Intervallo 1D:
$22.59
$23.59
Intervallo di 1 settimana:
$21.00
$24.75
Portata 52W:
$10.80
$24.75
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Nome
Inhibrx Biosciences Inc
Settore
Industria
Telefono
(858) 795-4220
Indirizzo
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Confronta INBX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
23.07 | 330.92M | 1.80M | 1.76B | -149.23M | 118.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-07-23 | Iniziato | JMP Securities | Mkt Perform |
| 2024-01-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-03-16 | Iniziato | SMBC Nikko | Outperform |
| 2021-09-21 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-09-14 | Iniziato | Credit Suisse | Outperform |
| 2020-09-14 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
Inhibrx Biosciences Inc Borsa (INBX) Ultime notizie
Why Inhibrx Biosciences Inc. stock is on top investor watchlistsSignificant capital appreciation - jammulinksnews.com
GHCL Limited (GHCL) Announces Strategic ShiftRapid portfolio appreciation - Autocar Professional
What drives Coastal Financial Corporation stock priceExceptional financial outcomes - Autocar Professional
What analysts say about Inhibrx Biosciences Inc. stockExceptional gains - Autocar Professional
Is Inhibrx Biosciences Inc. a good long term investmentTriple-digit returns - jammulinksnews.com
T.T. Limited (TTL) vs yyyExceptional earning trajectories - jammulinksnews.com
Is FCCO a good long term investmentRapid wealth multiplication - jammulinksnews.com
What analysts say about Appian Corporation stockRecord-setting profit potential - jammulinksnews.com
Top Quality Stocks Trusted Financial InsightsSuperior risk-adjusted returns - jammulinksnews.com
Is CAPL a good long term investmentOutstanding capital appreciation - jammulinksnews.com
What drives Inhibrx Biosciences Inc. stock priceRapid return acceleration - jammulinksnews.com
What analysts say about Drilling Tools International Corporation stockOutstanding risk-reward balance - Autocar Professional
How Technology Stocks Are Reshaping India’s Market Insider Stock RecommendationsTremendous return rates - Autocar Professional
Inhibrx Biosciences Inc. Stock Analysis and ForecastGame-changing returns - jammulinksnews.com
Top Stocks for Hedge Fund Investments Elite Trader Market TipsBreakthrough profit margins - PrintWeekIndia
Best Stocks for Aggressive Investors in India High Value Stock PicksBreakthrough profits - Autocar Professional
why ivda stock attracts strong analyst attentionFree Access to Community with 300% Return - Newser
What drives SERV stock priceHigh-performance investment picks - jammulinksnews.com
What drives PLAB stock priceExceptional stock performance - jammulinksnews.com
Inhibrx Biosciences: Seeing Soon If The Momentum Is Just Hype - Seeking Alpha
Why Inhibrx Biosciences Inc. stock attracts strong analyst attentionHigh Return Setup Scanner - beatles.ru
What makes Inhibrx Biosciences Inc. stock price move sharplyROI Driven Alerts - Newser
How Inhibrx Biosciences Inc. stock performs during market volatilitySmall Risk Large Return Trades - Newser
(INBX) Trading Signals - news.stocktradersdaily.com
Why INBX Is A Stock To Watch In 2025 - RTTNews
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) dropped from Russell Microcap Growth Index - MarketScreener
How To Trade (INBX) - news.stocktradersdaily.com
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) added to Russell 2000 Defensive Index - MarketScreener
Inhibrx Biosciences Concludes 2025 Annual Stockholders Meeting - TipRanks
Inhibrx Reports First Quarter 2025 Financial Results - BioSpace
Inhibrx Slashes Q1 Losses by 45%, Reveals Multiple Clinical Trial Readouts Coming in 2025 - Stock Titan
Oropharyngeal Cancer Treatment Market Size in 7MM is expected - openPR.com
Larynx Cancer Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight - openPR.com
Oropharyngeal Cancer Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight - Barchart.com
When the Price of (INBX) Talks, People Listen - news.stocktradersdaily.com
(INBX) On The My Stocks Page - news.stocktradersdaily.com
Change at the top for Phathom as Basta replaces Curran - BioCentury
Inhibrx Biosciences reshuffles leadership, appoints new CSO and President By Investing.com - Investing.com South Africa
Inhibrx Biosciences reshuffles leadership, appoints new CSO and President - Investing.com India
Inhibrx Biosciences Inc Azioni (INBX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):